RESEARCH
"Protein structure-based drug design is rapidly gaining momentum. The new opportunities, developments and results in this field are almost unbelievable ..."
Christophe L.M.J. Verlinde & Wim G.J. Hol (1994). Structure 2, 577-587. 
Follow the links to see
brief descriptions of research. 

Structure-based Design of Drugs
for Trypanosomiasis

Structure-based Design of Drugs
for Cholera and ETEC

New Algorithms
for Structure-based Drug Design

DNDI

MMV

SGPP

CEEH

Keck Center for Microbial Pathogens

Research in the Verlinde group is in the field of structure-based drug design. In addition, Dr. Verlinde participates in the SGPP consortium, a DNDI project, an MMV project, the Keck Center for Microbial Pathogens, and performs 3D protein structure analysis studies for the Center for Ecogenetics and Environmental Health (CEEH).

Group members: 

  • NN (post-doc)
New inhibitors of key trypanosomal enzymes and enterotoxigenic toxins are developed on the basis of crystal structures determined in the lab of Dr. Hol. Designed compounds are synthesized in the labs of Dr. Gelb and Dr. Fan. Because of approximations in the design methodology, especially the treatment of molecular flexibility and the the scoring of the molecular interactions, research relies heavily on the Drug Design Cycle. Also, efforts are underway to improve the scoring functions of molecular recognition.

Supported by NIH Grants GM-54,618 and AI-44,199.

Group alumni: 

  • Dr. Wendy Minke, now going by Wendy Sanderson, at Janssen Pharmaceutica in Belgium
  • Dr. David Diller, now at Pharmacopeia, Princeton
  • Dr. Xiao-Jian Tan, now a post-doc with Heather Carlson at U. Michigan at Ann Arbor
  • Dr. Oliver Hucke, now at Boehringer Ingelheim Canada, Laval, Quebec, Canada

 
contact: verlinde@u.washington.edu; tel: (206) 543 8865; fax: (206) 685 7002